Exelixis Inc
$ 53.50
1.75%
11 Jun - close price
- Market Cap 13,447,497,000 USD
- Current Price $ 53.50
- High / Low $ 53.93 / 52.49
- Stock P/E 17.72
- Book Value 7.63
- EPS 3.02
- Next Earning Report 2026-07-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.22 %
- ROE 0.41 %
- 52 Week High 53.93
- 52 Week Low 33.76
About
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Analyst Target Price
$49.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-10 | 2025-11-04 | 2025-07-28 | 2025-05-13 | 2025-02-11 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-06 | 2023-11-01 | 2023-08-01 |
| Reported EPS | 0.87 | 0.88 | 0.78 | 0.75 | 0.62 | 0.55 | 0.47 | 0.84 | 0.17 | 0.33 | 0.1 | 0.31 |
| Estimated EPS | 0.76 | 0.75 | 0.67 | 0.65 | 0.3666 | 0.49 | 0.42 | 0.37 | 0.29 | 0.31 | 0.19 | 0.22 |
| Surprise | 0.11 | 0.13 | 0.11 | 0.1 | 0.2534 | 0.06 | 0.05 | 0.47 | -0.12 | 0.02 | -0.09 | 0.09 |
| Surprise Percentage | 14.4737% | 17.3333% | 16.4179% | 15.3846% | 69.1217% | 12.2449% | 11.9048% | 127.027% | -41.3793% | 6.4516% | -47.3684% | 40.9091% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-27 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.75 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EXEL
2026-06-11 03:39:16
Goldman Sachs Group Inc. significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, purchasing over 1.1 million additional shares, raising its total holding to 2.1 million shares valued at approximately $92.7 million. Following this news, Exelixis shares rose by 2.4% and opened near their 52-week high, supported by strong earnings results. Despite mixed analyst sentiment, with an average "Hold" rating, several firms have recently raised their price targets for the biotechnology company.
2026-06-10 15:39:43
BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Exelixis, Inc. by 74.9% in the fourth quarter, now holding 43,658 shares valued at approximately $1.91 million. This comes as several insiders, including CFO Christopher J. Senner and Director Sue Gail Eckhardt, sold over $10 million worth of shares. Despite insider selling, Exelixis reported strong quarterly results with earnings of $0.87 per share on $610.81 million revenue, exceeding expectations, and currently holds a consensus "Hold" rating from analysts.
2026-06-10 03:39:16
Bank of New York Mellon Corp reduced its stake in Exelixis, Inc. by 12.3% during the fourth quarter, selling 285,584 shares. Despite this, other institutional investors like Goldman Sachs Group Inc. and BNP Paribas Financial Markets increased their holdings significantly. Exelixis reported strong first-quarter earnings, beating analyst estimates, and the company currently holds an average "Hold" rating from analysts with an average price target of $47.35.
2026-06-09 14:41:04
Exelixis Inc. (EXEL) stock reached an all-time high of $52.98, reflecting a 24.86% increase over the past year. The biotechnology company, currently valued at $13.34 billion, shows an attractive P/E ratio of 17.08 and a PEG ratio of 0.42, suggesting undervaluation and strong near-term earnings growth potential. Recent positive developments include exceeding Q1 2026 earnings and revenue expectations, a new collaboration with Merck for a phase 3 trial, and promising data from the phase 3 CABINET trial for cancer treatment.
2026-06-07 01:39:52
Exelixis, Inc. reported new phase 3 CABINET trial data for CABOMETYX in advanced neuroendocrine tumors, showing significant improvements in progression-free survival regardless of tumor functional status. These results expand the clinical evidence for CABOMETYX and reinforce its potential as a broad neuroendocrine tumor option, impacting investor considerations for EXEL stock which has seen strong returns. The article discusses both the clinical implications for physicians and the financial implications for investors, highlighting the growing oncology reach of Exelixis while also noting the concentration risk in a single drug.
2026-06-04 13:40:32
Exelixis director Sue Eckhardt sold 9,812 shares of the company's common stock for $491,973 on June 1, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, though InvestingPro analysis suggests it is still undervalued with excellent financial health. Following the transaction, Ms. Eckhardt directly holds 16,079 shares, including RSUs.
